Atherosclerosis in Rheumatoid Arthritis
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00037336 |
Recruitment Status :
Completed
First Posted : May 17, 2002
Last Update Posted : March 17, 2014
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Atherosclerosis Cardiovascular Diseases Heart Diseases Inflammation Arthritis, Rheumatoid |
BACKGROUND:
Premature cardiovascular disease is a major cause of mortality in rheumatoid arthritis (RA). The mechanisms underlying accelerated atherosclerosis and its relationship to inflammation in RA are poorly understood. Recent studies indicate that inflammation through the effects of inflammatory cytokines, and oxidative stress, through lipid peroxidation, are important in the pathogenesis of atherosclerosis. The study's hypothesis is that accelerated, inflammation-promoted atherosclerosis occurs in RA.
DESIGN NARRATIVE:
The study tests the hypotheses: 1) that structural and functional vascular damage is more frequent and more severe in patients with established RA than matched controls and is related to cumulative disease severity; 2) that this impairment of vascular integrity is associated with clinical and laboratory markers of inflammation, plasma homocysteine concentrations, and oxidative stress. To address these two hypotheses the relationship between longstanding inflammation and vascular integrity will be determined in a cross-sectional study of 75 patients with established RA in whom prospectively obtained clinical data are available for 15 years, and 75 matched non-RA controls. Endothelium-dependent, flow-mediated dilation of the brachial artery measured by ultrasound, and coronary calcium volume measured by electron beam computed tomography (EBCT) will provide functional and structural measures of vascular integrity, respectively. F2-isoprostane excretion, a reliable index of lipid peroxidation in vivo, homocysteine and lipid concentrations will be measured. Vascular integrity, oxidative stress, lipids and homocysteine will be compared in controls and RA patients. In the RA patients the relationship between RA activity and damage indices obtained over 15 years and vascular function and damage measures will be determined. Using the same techniques we will address hypothesis 3) that the rate of progression of vascular disease in patients with early RA can be altered by control of inflammation. In a prospective cohort of 100 patients with early RA receiving usual clinical care and 100 matched non-RA controls followed over 24 months the relationship between clinical and biochemical measures of inflammation and vascular integrity will be determined by comparing "responders" and "non-responders". These studies will provide a basic understanding of the interrelationship between inflammation, lipids, oxidative stress and vascular damage, and will suggest strategies for reversing or preventing such damage in RA and, potentially, other diseases.
Study Type : | Observational |
Study Start Date : | September 2001 |
Actual Primary Completion Date : | July 2007 |
Actual Study Completion Date : | July 2007 |


Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00037336
Principal Investigator: | Charles Stein | Vanderbilt University |
Responsible Party: | C. Michael Stein, Professor of Medicine, Vanderbilt University |
ClinicalTrials.gov Identifier: | NCT00037336 |
Other Study ID Numbers: |
1163 R01HL067964 ( U.S. NIH Grant/Contract ) |
First Posted: | May 17, 2002 Key Record Dates |
Last Update Posted: | March 17, 2014 |
Last Verified: | March 2014 |
Arthritis Arthritis, Rheumatoid Cardiovascular Diseases Heart Diseases Atherosclerosis Inflammation Joint Diseases Musculoskeletal Diseases |
Pathologic Processes Arteriosclerosis Arterial Occlusive Diseases Vascular Diseases Rheumatic Diseases Connective Tissue Diseases Autoimmune Diseases Immune System Diseases |